Stock MNOV MEDICINOVA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News MediciNova, Inc.

Equities

MNOV

US58468P2065

Market Closed - Nasdaq
Other stock markets
 21:00:00 28/06/2024 BST 		5-day change 1st Jan Change
1.44 USD 0.00% Intraday chart for MediciNova, Inc. +3.60% -4.00%
06-05 MediciNova Receives Notice of Allowance for New Patent Covering MN-166 for the Prevention of Metastasis of Various Solid Cancer CI
06-03 MediciNova, Inc. Announces Data from Phase 1B/2A Clinical Trial of Mn-166 in Glioblastoma Patients At the American Society of Clinical Oncology Annual Meeting 2024 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations
GL
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 for the Prevention of Metastasis of Various Solid Cancer
AQ
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer
GL
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer
AQ
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 for the Prevention of Metastasis of Various Solid Cancer
CI
MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
GL
MediciNova, Inc. Announces Data from Phase 1B/2A Clinical Trial of Mn-166 in Glioblastoma Patients At the American Society of Clinical Oncology Annual Meeting 2024
CI
MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 for Cardiometabolic Conditions
AQ
MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions
GL
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer
GL
MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 for the Prevention of Metastasis of Eye Cancer
CI
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome
GL
MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome
CI
MediciNova: Q1 Earnings Snapshot
AQ
MediciNova, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)
GL
MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)
AQ
MediciNova, Inc. Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166
CI
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting
AQ
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MNOV Stock
  4. News MediciNova, Inc.